

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.
2. (Original) The method of claim 1, wherein the inhibitor of PRAME is an siRNA or vector encoding said siRNA.
3. (Currently Amended) The method of claim 1-~~or 2~~ wherein said HDACi is N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide.
4. (Currently Amended) The method of claim 1, ~~2 or 3~~ wherein said tumour is a melanoma.
5. (Original) An inhibitor of PRAME and a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid, as a combined preparation for simultaneous, separate or sequential use in therapy.
6. (Original) An inhibitor and second agent for use according to claim 5 wherein said therapy is treatment of a melanoma.

7. (Currently Amended) An inhibitor and second agent for use according to claim 5 or 6 wherein said inhibitor of PRAME is an siRNA or vector encoding said siRNA.
8. (Currently Amended) An inhibitor and second agent for use according to claim 5, 6 or 7 wherein said HDACi is N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide.
9. (Original) Use of an inhibitor of PRAME in combination with an HDACi or a retinoid for the manufacture of a medicament as a combined preparation for simultaneous, separate or sequential use in the treatment of a tumour.
10. (Original) Use of an HDACi or a retinoid, for treating a tumour in a subject, wherein the subject has received treatment so as to suppress the level of PRAME in the tumour at the time of HDACi or retinoid administration.
11. (Currently Amended) Use according to claim 9 ~~or claim 10~~ wherein said tumour is a melanoma.
12. (Original) An assay for an inhibitor of an interaction between PRAME and a retinoic acid receptor (RAR) which comprises bringing together:
 - (i) a candidate inhibitor; and
 - (ii) a PRAME protein and a RAR protein; and

BERNARDS ET AL.

Appl. No. Unknown

July 24, 2006

determining if the putative inhibitor is capable of preventing an interaction between said PRAME and RAR proteins.